Global Mitral Regurgitation Market 2025 by Company, Regions, Type and Application, Forecast to 2031
Description
According to our (Global Info Research) latest study, the global Mitral Regurgitation market size was valued at US$ million in 2024 and is forecast to a readjusted size of USD million by 2031 with a CAGR of %during review period.
Mitral regurgitation (MR) is the backflow of blood from the left ventricle into the left atrium during left ventricular systole. The mitral valve is located in the opening between the left atrium and the left ventricle. It opens to allow blood from the left atrium to fill the left ventricle. When the left ventricle contracts, the mitral valve closes so that pumped blood can only flow into the aorta. When the mitral valve is not fully closed, some blood can leak back into the left atrium. Mitral regurgitation can be divided into primary and secondary MR according to the pathogenesis. Primary mitral regurgitation is due to the pathological changes of one or more of the mitral valve leaflets, valve annulus, chordae tendineae and papillary muscles, such as degenerative disease or rheumatic disease, which cause the mitral valve to fail to close normally. Secondary mitral valve regurgitation is functional mitral valve regurgitation, which is caused by the disease of the heart itself or the valve supporting structure, such as pathological changes of the myocardium leading to pathological dilatation of the left ventricle and mitral valve annulus or Mitral regurgitation due to localized displacement of the left ventricle and subvalvular device. The current quantitative assessment of mitral valve regurgitation, the current standards of various guidelines and documents are not completely consistent, generally divided into mild, moderate and severe, this classification is relatively broad, can not well reflect the changes and manifestations before and after surgery effect of surgery. In the MitraClip system clinical trial, mitral regurgitation was divided into no (0+), mild (1+), moderate (2+), moderate to severe (3+), severe (4+), and then more This classification method is used in several clinical studies of mitral valve regurgitation interventional therapy.
This report is a detailed and comprehensive analysis for global Mitral Regurgitation market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Mitral Regurgitation market size and forecasts, in consumption value ($ Million), 2020-2031
Global Mitral Regurgitation market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global Mitral Regurgitation market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global Mitral Regurgitation market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Mitral Regurgitation
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Mitral Regurgitation market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Edwards Lifesciences, Abbott, CardioSolution, NeoChord, Mitralign, Medtronic, Boston Scientific, Mitralix, Shanghai Hanyu Medical Technology, Valgen Holding Corporation, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Mitral Regurgitation market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Primary Mitral Regurgitation
Secondary Mitral Regurgitation
Market segment by Application
Transapical
Via Stock and Via Interstitial
Right Internal Jugular Vein
Market segment by players, this report covers
Edwards Lifesciences
Abbott
CardioSolution
NeoChord
Mitralign
Medtronic
Boston Scientific
Mitralix
Shanghai Hanyu Medical Technology
Valgen Holding Corporation
NeoChord
CoreMedic
Babic Chord
Gore Medical
Valtech Cardio
Transcardiac
ChoRe
AVVIE
Cardiovalve
HighLife SAS
Neovasc
MitrAssist Lifesciences
Shanghai NewMed Medical
Peijia Medical
MicroPort CardioFlow Medtech
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Mitral Regurgitation product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Mitral Regurgitation, with revenue, gross margin, and global market share of Mitral Regurgitation from 2020 to 2025.
Chapter 3, the Mitral Regurgitation competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Mitral Regurgitation market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Mitral Regurgitation.
Chapter 13, to describe Mitral Regurgitation research findings and conclusion.
Mitral regurgitation (MR) is the backflow of blood from the left ventricle into the left atrium during left ventricular systole. The mitral valve is located in the opening between the left atrium and the left ventricle. It opens to allow blood from the left atrium to fill the left ventricle. When the left ventricle contracts, the mitral valve closes so that pumped blood can only flow into the aorta. When the mitral valve is not fully closed, some blood can leak back into the left atrium. Mitral regurgitation can be divided into primary and secondary MR according to the pathogenesis. Primary mitral regurgitation is due to the pathological changes of one or more of the mitral valve leaflets, valve annulus, chordae tendineae and papillary muscles, such as degenerative disease or rheumatic disease, which cause the mitral valve to fail to close normally. Secondary mitral valve regurgitation is functional mitral valve regurgitation, which is caused by the disease of the heart itself or the valve supporting structure, such as pathological changes of the myocardium leading to pathological dilatation of the left ventricle and mitral valve annulus or Mitral regurgitation due to localized displacement of the left ventricle and subvalvular device. The current quantitative assessment of mitral valve regurgitation, the current standards of various guidelines and documents are not completely consistent, generally divided into mild, moderate and severe, this classification is relatively broad, can not well reflect the changes and manifestations before and after surgery effect of surgery. In the MitraClip system clinical trial, mitral regurgitation was divided into no (0+), mild (1+), moderate (2+), moderate to severe (3+), severe (4+), and then more This classification method is used in several clinical studies of mitral valve regurgitation interventional therapy.
This report is a detailed and comprehensive analysis for global Mitral Regurgitation market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Mitral Regurgitation market size and forecasts, in consumption value ($ Million), 2020-2031
Global Mitral Regurgitation market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global Mitral Regurgitation market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global Mitral Regurgitation market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Mitral Regurgitation
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Mitral Regurgitation market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Edwards Lifesciences, Abbott, CardioSolution, NeoChord, Mitralign, Medtronic, Boston Scientific, Mitralix, Shanghai Hanyu Medical Technology, Valgen Holding Corporation, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Mitral Regurgitation market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Primary Mitral Regurgitation
Secondary Mitral Regurgitation
Market segment by Application
Transapical
Via Stock and Via Interstitial
Right Internal Jugular Vein
Market segment by players, this report covers
Edwards Lifesciences
Abbott
CardioSolution
NeoChord
Mitralign
Medtronic
Boston Scientific
Mitralix
Shanghai Hanyu Medical Technology
Valgen Holding Corporation
NeoChord
CoreMedic
Babic Chord
Gore Medical
Valtech Cardio
Transcardiac
ChoRe
AVVIE
Cardiovalve
HighLife SAS
Neovasc
MitrAssist Lifesciences
Shanghai NewMed Medical
Peijia Medical
MicroPort CardioFlow Medtech
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Mitral Regurgitation product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Mitral Regurgitation, with revenue, gross margin, and global market share of Mitral Regurgitation from 2020 to 2025.
Chapter 3, the Mitral Regurgitation competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Mitral Regurgitation market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Mitral Regurgitation.
Chapter 13, to describe Mitral Regurgitation research findings and conclusion.
Table of Contents
151 Pages
- 1 Market Overview
- 2 Company Profiles
- 3 Market Competition, by Players
- 4 Market Size Segment by Type
- 5 Market Size Segment by Application
- 6 North America
- 7 Europe
- 8 Asia-Pacific
- 9 South America
- 10 Middle East & Africa
- 11 Market Dynamics
- 12 Industry Chain Analysis
- 13 Research Findings and Conclusion
- 14 Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
